JP Morgan Chase’s Clearside Biomedical CLSD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-46
| Closed | -$183 | – | 7479 |
|
|
2025
Q3 | $183 | Sell |
46
-10
| -18% | -$68 | ﹤0.01% | 7118 |
|
|
2025
Q2 | $672 | Sell |
56
-609
| -92% | -$7.56K | ﹤0.01% | 6665 |
|
|
2025
Q1 | $9.16K | Sell |
665
-26
| -4% | -$373 | ﹤0.01% | 6324 |
|
|
2024
Q4 | $9.84K | Hold |
691
| – | – | ﹤0.01% | 6392 |
|
|
2024
Q3 | $13.2K | Sell |
691
-4
| -0.6% | -$68 | ﹤0.01% | 6318 |
|
|
2024
Q2 | $13.5K | Sell |
695
-11
| -2% | -$213 | ﹤0.01% | 6210 |
|
|
2024
Q1 | $16.2K | Buy |
706
+492
| +230% | +$10.6K | ﹤0.01% | 6267 |
|
|
2023
Q4 | $3.75K | Buy |
214
+2
| +0.9% | +$29 | ﹤0.01% | 6611 |
|
|
2023
Q3 | $2.77K | Sell |
212
-60
| -22% | -$909 | ﹤0.01% | 6489 |
|
|
2023
Q2 | $4.57K | Buy |
272
+64
| +31% | +$1.1K | ﹤0.01% | 6189 |
|
|
2023
Q1 | $3K | Sell |
208
-717
| -78% | -$13.9K | ﹤0.01% | 6338 |
|
|
2022
Q4 | $15K | Buy |
925
+182
| +24% | +$3.28K | ﹤0.01% | 5957 |
|
|
2022
Q3 | $12K | Sell |
743
-468
| -39% | -$10.3K | ﹤0.01% | 5926 |
|
|
2022
Q2 | $27K | Buy |
1,211
+608
| +101% | +$14.8K | ﹤0.01% | 5822 |
|
|
2022
Q1 | $21K | Buy |
603
+119
| +25% | +$3.56K | ﹤0.01% | 6057 |
|
|
2021
Q4 | $20K | Buy |
484
+351
| +264% | +$22.7K | ﹤0.01% | 6214 |
|
|
2021
Q3 | $12K | Sell |
133
-367
| -73% | -$32.4K | ﹤0.01% | 6131 |
|
|
2021
Q2 | $37K | Buy |
500
+167
| +50% | +$7.76K | ﹤0.01% | 5812 |
|
|
2021
Q1 | $12K | Buy |
333
+166
| +99% | +$8.34K | ﹤0.01% | 5772 |
|
|
2020
Q4 | $7K | Sell |
167
-266
| -61% | -$6.9K | ﹤0.01% | 5418 |
|
|
2020
Q3 | $10K | Buy |
433
+100
| +30% | +$2.58K | ﹤0.01% | 5251 |
|
|
2020
Q2 | $9K | Hold |
333
| – | – | ﹤0.01% | 5135 |
|
|
2020
Q1 | $9K | Sell |
333
-1,400
| -81% | -$51.8K | ﹤0.01% | 5060 |
|
|
2019
Q4 | $75K | Buy |
1,733
+1,043
| +151% | +$21.9K | ﹤0.01% | 4993 |
|
|
2019
Q3 | $6K | Sell |
690
-664
| -49% | -$9.52K | ﹤0.01% | 5546 |
|
|
2019
Q2 | $20K | Sell |
1,354
-455
| -25% | -$8.11K | ﹤0.01% | 5436 |
|
|
2019
Q1 | $38K | Sell |
1,809
-2,944
| -62% | -$58.4K | ﹤0.01% | 5221 |
|
|
2018
Q4 | $77K | Sell |
4,753
-14,555
| -75% | -$683K | ﹤0.01% | 4940 |
|
|
2018
Q3 | $1.78M | Buy |
19,308
+16,932
| +713% | +$2.01M | ﹤0.01% | 3539 |
|
|
2018
Q2 | $381K | Sell |
2,376
-7,153
| -75% | -$1.21M | ﹤0.01% | 4292 |
|
|
2018
Q1 | $1.53M | Buy |
9,529
+9,232
| +3,108% | +$1.12M | ﹤0.01% | 3431 |
|
|
2017
Q4 | $31K | Buy |
+297
| New | +$31.9K | ﹤0.01% | 5050 |
|
|
2017
Q3 | – | Sell |
-231
| Closed | -$32K | – | 4983 |
|
|
2017
Q2 | $32K | Sell |
231
-1,264
| -85% | -$152K | ﹤0.01% | 4433 |
|
|
2017
Q1 | $178K | Buy |
+1,495
| New | +$176K | ﹤0.01% | 4115 |
|
|
2016
Q4 | – | Sell |
-185
| Closed | -$48K | – | 5008 |
|
|
2016
Q3 | $48K | Buy |
+185
| New | +$22.7K | ﹤0.01% | 4044 |
|
Other funds holding CLSD
JP Morgan Chase's CLSD Position: Q4 2025 in Review
JP Morgan Chase sold out of Clearside Biomedical (CLSD) in Q4 2025, closing a stake of 46 shares — an estimated $183 sold.
JP Morgan Chase first reported a position in CLSD in Q3 2016 and held it in 35 quarters. The position peaked at $1.78M in Q3 2018. 1 fund tracked by Wall St. Rank holds CLSD as of Q4 2025.
- JP Morgan Chase reported no remaining Clearside Biomedical position as of Q4 2025 after selling out during the quarter.
- JP Morgan Chase sold 46 Clearside Biomedical shares in Q4 2025, an estimated $183.
- JP Morgan Chase first reported a position in Clearside Biomedical in Q3 2016 and held it in 35 quarters.
- JP Morgan Chase's Clearside Biomedical position peaked at $1.78M in Q3 2018.
- 1 fund tracked by Wall St. Rank held Clearside Biomedical as of Q4 2025.
Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.